Everything published about PT-141: mechanism, research areas, results, regimens, risks, comparisons — plus the dated Vietnam price and ordering rules.
| Format | Price (index Nov 2, 2026) | Delivery |
|---|---|---|
| 10 mg | from 1 300 000 ₫ | Da Nang ~30 min · Vietnam 1–2 days |
PT-141, or bremelanotide, is a melanocortin-receptor agonist studied in sexual-desire pathways. Its action is primarily through central signalling rather than the direct vascular mechanism of PDE5 inhibitors.
A licensed pharmaceutical formulation is indicated for acquired, generalised hypoactive sexual desire disorder in eligible premenopausal women. Other sexual-function uses remain distinct research questions.
A centrally acting peptide with a specific licensed role in low sexual desire, distinct from blood-flow-focused treatments.
Pivotal studies in eligible premenopausal women found improvements in sexual desire and related distress. That clinical effect is about desire, rather than a direct blood-flow or guaranteed performance effect.
On-demand protocols: Commonly discussed lower-dose schedules: 0.5–1 mg subcutaneously around two hours before activity. Another research-community range: 1–1.75 mg, 1–2 hours beforehand. The licensed pharmaceutical dose is 1.75 mg at least 45 minutes beforehand. The licensed limits are no more than one dose in 24 hours and eight doses per month.
Nausea, flushing, headache and injection-site reactions are common. Temporary blood-pressure elevation and skin darkening can occur; uncontrolled hypertension and known cardiovascular disease are licensed contraindications.
PT-141 acts through central melanocortin signalling, while sildenafil acts through the vascular PDE5 pathway. Desire and erection-related outcomes reflect different mechanisms.
from 1 300 000 ₫ for 10 mg (index Nov 2, 2026); final total confirmed in writing before payment.
No: research material, not a prescription drug; no medical claims.